

The Therapeutic Efficacy and Clinical Implications of Vericiguat in the Management of Heart Failure with Reduced Ejection Fraction (HFrEF)

Donaldo Emiliano Silva Lopez^{*1}, Sebastián Jiménez Andrade², Emilio Jimenez Andrade¹, Mariana Alejandra Prieto Montoya³, Jessica Lizbeth Raygoza Robles³, Sarai Fonseca Martínez³

¹Tecnológico de Monterrey campus Monterrey, Mexico.

²Universidad Anáhuac México.

³Universidad Cuauhtémoc Plantel Aguascalientes, Mexico.

ABSTRACT

Heart failure with reduced ejection fraction (HFrEF) remains a formidable clinical challenge, necessitating innovative pharmacological interventions to mitigate morbidity and mortality. Vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, has emerged as a promising therapeutic agent, targeting the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway to enhance myocardial and vascular function. The pivotal VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial demonstrated a significant reduction in the composite endpoint of cardiovascular death or heart failure hospitalization in high-risk HFrEF patients when vericiguat was added to standard guideline-directed medical therapy (GDMT). This article comprehensively reviews the pharmacodynamic and pharmacokinetic properties of vericiguat, its mechanistic role in HFrEF pathophysiology, and the critical findings from the VICTORIA trial. Furthermore, we discuss the clinical implications of vericiguat in contemporary HFrEF management, including its potential integration into existing therapeutic algorithms and its impact on patient-centered outcomes.

KEYWORDS: Vericiguat, heart failure with reduced ejection fraction (HFrEF), soluble guanylate cyclase (sGC) stimulator, VICTORIA trial, cardiovascular outcomes, guideline-directed medical therapy (GDMT), nitric oxide pathway, myocardial dysfunction, pharmacotherapy.

ARTICLE DETAILS

Published On:
18 August 2025

Available on:
<https://ijmscrs.com>

INTRODUCTION

Heart failure with reduced ejection fraction (HFrEF) is a complex, progressive syndrome characterized by impaired ventricular systolic function, neurohormonal activation, and systemic endothelial dysfunction, culminating in high rates of hospitalization and mortality. Despite advancements in guideline-directed medical therapy (GDMT), including beta-blockers, angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i), a substantial residual risk persists, underscoring the need for novel therapeutic strategies. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays a pivotal role in cardiovascular homeostasis, and its impairment contributes to myocardial

stiffness, ventricular remodeling, and endothelial dysfunction in HFrEF.^{1,2}

Vericiguat, a first-in-class oral sGC stimulator, enhances cGMP production independently of NO availability, offering a unique mechanism to counteract pathological signaling in HFrEF. The VICTORIA trial, a multicenter, randomized, double-blind, placebo-controlled study, evaluated the efficacy and safety of vericiguat in high-risk HFrEF patients with recent decompensation. The trial demonstrated a statistically significant reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization, positioning vericiguat as a potential adjunctive therapy in this vulnerable population. This article explores the mechanistic rationale for vericiguat use in HFrEF, analyzes key data from the VICTORIA trial, and

The Therapeutic Efficacy and Clinical Implications of Vericiguat in the Management of Heart Failure with Reduced Ejection Fraction (HFrEF)

evaluates its place in therapy amidst evolving HFrEF treatment paradigms. By integrating clinical trial evidence with pathophysiological insights, we aim to elucidate the role of vericiguat in optimizing outcomes for patients with HFrEF.^{3,4}

Clinical Trials Supporting the Use of Vericiguat in Heart Failure with Reduced Ejection Fraction (HFrEF)

The therapeutic potential of vericiguat in HFrEF is substantiated by a series of rigorously conducted clinical trials, with the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial standing as the cornerstone of its evidence base. This landmark study, a multicenter, randomized, double-blind, placebo-controlled trial, enrolled patients with chronic HFrEF who had experienced recent clinical decompensation, positioning them at high risk for adverse cardiovascular outcomes. The trial demonstrated that vericiguat, when added to guideline-directed medical therapy (GDMT), significantly reduced the composite primary endpoint of cardiovascular death or first hospitalization for heart failure, establishing its role as a disease-modifying agent in this high-risk cohort.⁵

Prior to VICTORIA, the SOCRATES-REDUCED (Soluble Guanylate Cyclase Stimulator in Heart Failure Patients with Reduced Ejection Fraction) trial provided critical early-phase evidence on the pharmacodynamic effects and safety profile of vericiguat in HFrEF patients. This dose-finding study explored various dosages of vericiguat and assessed its impact on biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP), revealing favorable hemodynamic and neurohormonal modulation without significant safety concerns. Although SOCRATES-REDUCED was not powered for hard clinical endpoints, it laid the foundation for subsequent investigations by confirming the drug's mechanism of action—enhancing cyclic guanosine monophosphate (cGMP) signaling independently of nitric oxide (NO) bioavailability, thereby counteracting myocardial and vascular dysfunction in HFrEF.⁵

Further supporting evidence arises from mechanistic studies and post-hoc analyses of the VICTORIA trial, which elucidated the drug's benefit across key subgroups, including patients with ischemic versus non-ischemic cardiomyopathy, those with varying baseline NT-proBNP levels, and individuals on concomitant therapies such as sacubitril/valsartan or SGLT2 inhibitors. These analyses reinforced the notion that vericiguat provides incremental clinical benefit even in the context of optimized background therapy, underscoring its role as an adjunctive treatment in advanced HFrEF.⁶

Collectively, these trials underscore vericiguat's capacity to address unmet needs in HFrEF management, particularly in high-risk patients with recent worsening heart failure. By targeting the NO-sGC-cGMP pathway—a therapeutic axis previously underexploited in HFrEF—vericiguat

complements existing neurohormonal blockade strategies, offering a novel approach to reducing morbidity and mortality in this challenging patient population. The consistency of these findings across clinical and biomarker-driven outcomes solidifies vericiguat's position within the evolving HFrEF treatment paradigm.⁷

Pathophysiological Rationale for Vericiguat in Heart Failure with Reduced Ejection Fraction (HFrEF)

The pathogenesis of heart failure with reduced ejection fraction (HFrEF) is characterized by a complex interplay of neurohormonal hyperactivity, endothelial dysfunction, myocardial remodeling, and impaired nitric oxide (NO)-mediated signaling, culminating in progressive ventricular dysfunction and systemic maladaptive responses. Central to this pathophysiology is the dysregulation of the NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway, a critical modulator of vascular tone, myocardial contractility, and anti-fibrotic signaling. In HFrEF, reduced NO bioavailability due to endothelial dysfunction, oxidative stress, and upregulated phosphodiesterases (PDEs) leads to diminished sGC activation, resulting in insufficient cGMP production. This deficiency exacerbates ventricular stiffness, vasoconstriction, and cardiomyocyte hypertrophy, perpetuating a vicious cycle of hemodynamic deterioration and clinical decompensation.⁸ Vericiguat, a first-in-class oral sGC stimulator, addresses this pathophysiological deficit by directly enhancing sGC activity in a NO-independent manner, thereby restoring cGMP signaling even in the setting of endothelial dysfunction. Unlike traditional vasodilators that rely on endogenous NO, vericiguat exhibits dual activity: it sensitizes sGC to endogenous NO while also directly stimulating the enzyme in the absence of NO, ensuring sustained cGMP production. This dual mechanism confers potent vasodilatory, anti-fibrotic, and cardioprotective effects, mitigating adverse ventricular remodeling and improving myocardial compliance.⁸

The VICTORIA trial provided robust clinical validation of this mechanistic rationale by demonstrating that vericiguat significantly reduced the composite endpoint of cardiovascular death and heart failure hospitalization in high-risk HFrEF patients with recent decompensation. The trial's population—enriched with individuals exhibiting elevated natriuretic peptides and a history of worsening HF—reflects a subset with profound NO-sGC-cGMP pathway impairment, making them particularly responsive to vericiguat's therapeutic effects. Post-hoc analyses further suggested that the drug's benefits were consistent across various subgroups, reinforcing its role in counteracting the maladaptive molecular cascades that drive HF progression.⁹

Beyond hemodynamic improvements, vericiguat's ability to modulate myocardial fibrosis, inflammation, and oxidative stress underscores its pleiotropic benefits in HFrEF. By augmenting cGMP signaling, it inhibits pro-fibrotic

The Therapeutic Efficacy and Clinical Implications of Vericiguat in the Management of Heart Failure with Reduced Ejection Fraction (HFrEF)

transforming growth factor-beta (TGF- β) pathways, attenuates cardiac myocyte apoptosis, and enhances vascular smooth muscle relaxation, collectively contributing to improved cardiac output and clinical stability.⁹

In summary, the pathophysiological foundation for vericiguat in HFrEF lies in its capacity to rectify the dysfunctional NO-sGC-cGMP axis—a key contributor to disease progression. The VICTORIA trial's findings not only confirm this mechanistic premise but also establish vericiguat as a pivotal therapeutic option in the contemporary management of HFrEF, particularly for patients with high residual risk despite optimal guideline-directed medical therapy.¹⁰

Therapeutic Indications and Contraindications for Vericiguat in Heart Failure with Reduced Ejection Fraction (HFrEF): Clinical Considerations and Evidence from the VICTORIA Trial

Indications for Vericiguat in HFrEF

Vericiguat is indicated as a disease-modifying pharmacotherapy for patients with chronic heart failure with reduced ejection fraction (HFrEF; LVEF <45%) who remain at high risk of clinical deterioration despite being on maximally tolerated guideline-directed medical therapy (GDMT). Its use is particularly supported in individuals with a recent history of acute decompensated heart failure (ADHF) requiring hospitalization or intravenous diuretic therapy, as this population was specifically enrolled in the VICTORIA trial, where vericiguat demonstrated a significant reduction in the composite endpoint of cardiovascular mortality and recurrent heart failure hospitalizations.¹¹

The drug's mechanism of action—stimulation of soluble guanylate cyclase (sGC), thereby enhancing cyclic guanosine monophosphate (cGMP) signaling—makes it a valuable adjunct in HFrEF patients exhibiting persistent symptoms (NYHA Class II-IV) and elevated natriuretic peptides (BNP or NT-proBNP), biomarkers reflective of ongoing neurohormonal activation and endothelial dysfunction. Given its complementary pathway modulation, vericiguat is suitable for use alongside beta-blockers, renin-angiotensin-aldosterone system inhibitors (RAASi), mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i), without significant pharmacokinetic interactions.¹¹

Contraindications and Precautions in Clinical Use

Despite its therapeutic benefits, vericiguat is absolutely contraindicated in patients with a known hypersensitivity reaction to the drug or its excipients, as well as in those with severe hepatic impairment (Child-Pugh Class C) due to insufficient pharmacokinetic data in this population. Additionally, its use is not recommended in pregnant women, as animal studies suggest potential embryotoxic effects mediated by cGMP pathway modulation, warranting strict

contraception measures in women of childbearing potential.¹²

A critical consideration is the risk of symptomatic hypotension, particularly in patients with baseline systolic blood pressure <100 mmHg or those on concomitant vasodilators (e.g., nitrates, hydralazine) or phosphodiesterase-5 (PDE5) inhibitors, given the pharmacodynamic overlap in cGMP potentiation. The VICTORIA trial reported a higher incidence of hypotension-related adverse events in the vericiguat arm, necessitating blood pressure monitoring and gradual dose titration (starting at 2.5 mg once daily, up to 10 mg) to mitigate this risk.^{13,14} Furthermore, vericiguat has not been studied in acute decompensated HF without prior stabilization, cardiogenic shock, or advanced end-stage HF requiring inotropic support, and thus should be avoided in these high-risk scenarios. Caution is also advised in patients with severe renal impairment (eGFR <15 mL/min/1.73 m² or on dialysis), as limited data exist regarding drug accumulation, though no dose adjustments are currently required for mild-to-moderate renal dysfunction.¹⁵

CONCLUSION

Balancing Efficacy and Safety in Clinical Practice

The VICTORIA trial solidified vericiguat's role in high-risk HFrEF, but its application must be guided by individualized risk assessment, particularly regarding hemodynamic stability and concomitant medications. While it offers a novel therapeutic strategy for reducing morbidity and mortality in chronic HFrEF, adherence to contraindications and cautious dosing remains paramount to optimizing clinical outcomes while minimizing adverse effects.

The advent of vericiguat represents a significant therapeutic breakthrough in the management of heart failure with reduced ejection fraction (HFrEF), addressing a critical pathophysiological gap in current treatment paradigms. As a novel oral soluble guanylate cyclase (sGC) stimulator, vericiguat uniquely targets the impaired nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) signaling pathway, a fundamental molecular derangement contributing to myocardial dysfunction, ventricular remodeling, and disease progression in HFrEF. The landmark VICTORIA trial has unequivocally demonstrated that pharmacological enhancement of this pathway through vericiguat administration, when added to optimal guideline-directed medical therapy (GDMT), confers statistically significant and clinically meaningful reductions in the composite endpoint of cardiovascular mortality and heart failure hospitalization in high-risk patients with recent decompensation.

The mechanistic elegance of vericiguat lies in its dual capacity to both sensitize sGC to endogenous NO and directly stimulate the enzyme independently of NO bioavailability, thereby circumventing the endothelial dysfunction characteristic of advanced HFrEF. This distinctive

The Therapeutic Efficacy and Clinical Implications of Vericiguat in the Management of Heart Failure with Reduced Ejection Fraction (HFrEF)

pharmacodynamic profile translates into multifaceted cardioprotective effects, including improved ventricular-vascular coupling, attenuation of pathological remodeling, and modulation of neurohormonal activation, without exhibiting the tachyphylaxis or tolerance phenomena associated with conventional nitrate therapy. Importantly, the therapeutic benefits observed in the VICTORIA population - predominantly comprising patients with markedly elevated natriuretic peptides and frequent prior hospitalizations - underscore vericiguat's potential to modify disease trajectory in precisely those patients who remain at highest risk despite contemporary treatment strategies.

From a clinical implementation perspective, vericiguat expands our therapeutic armamentarium by offering a well-tolerated, once-daily oral agent with a favorable safety profile, suitable for use across a broad spectrum of HFrEF patients. Its complementary mechanism of action facilitates seamless integration with established pillars of HFrEF management, including beta-adrenergic antagonists, renin-angiotensin-aldosterone system inhibitors, and sodium-glucose cotransporter-2 inhibitors, without significant pharmacokinetic interactions. The practical titration protocol, initiated at 2.5 mg daily with gradual up-titration to the target 10 mg dose, allows for careful hemodynamic monitoring and enhances tolerability, particularly in patients with marginal blood pressure.

While the impressive results from VICTORIA have positioned vericiguat as a valuable addition to contemporary HFrEF management algorithms, several important considerations warrant emphasis. The drug's benefit appears most pronounced in patients with recent worsening heart failure, suggesting that optimal patient selection should focus on this high-risk phenotype. Furthermore, ongoing investigations are needed to elucidate potential differential effects across various HFrEF subpopulations and to define its role relative to other emerging therapies. The absence of significant renal excretion and lack of requirement for dose adjustment in renal impairment represent particularly advantageous features for a condition frequently complicated by chronic kidney disease.

In conclusion, vericiguat embodies a paradigm shift in HFrEF therapeutics by targeting a previously underutilized pathogenic pathway with precision pharmacology. The robust evidence from VICTORIA, coupled with its mechanistic rationale and practical administration profile, solidifies vericiguat's position as an important therapeutic option for improving outcomes in high-risk HFrEF patients. As we continue to refine our understanding of its long-term effects and optimal use patterns, vericiguat stands poised to make a substantial impact on the global burden of heart failure, offering new hope for a patient population with persistently high unmet clinical needs. Its incorporation into treatment algorithms represents a significant advancement in

our ongoing quest to mitigate the substantial morbidity and mortality associated with this devastating syndrome.

REFERENCES

- I. Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. *AME Med J* [Internet]. 2020;5.. Available from: <https://amj.amegroups.com/article/view/5475>.
- II. Tanai E, Frantz S. Pathophysiology of heart failure. *Comprehensive Physiology* [Internet]. John Wiley & Sons, Ltd; 2015. p. 187–214. <https://onlinelibrary.wiley.com/doi/abs/10.1002/cphy.c140055>.
- III. Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: a systematic review and meta-analysis. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596421/#B2>.
- IV. FDA approves vericiguat for reducing cardiovascular death and heart failure Available from: <https://www.uspharmacist.com/article/fda-approves-vericiguat-for-reducing-cardiovascular-death-and-heart-failure>.
- V. Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. *JAMA* [Internet] 2020;324:488. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2768982>.
- VI. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure [Internet]. 2022 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203591/>.
- VII. Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (vericiguat global study in subjects with HFrEF) trial. *Eur J Heart Fail* 2021;23:1313–21.
- VIII. Cochrane Handbook for Systematic Reviews of Interventions Cochrane Training [Internet]. 2022. Available from: <https://training.cochrane.org/handbook#how-to-access>.
- IX. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews -PubMed [Internet] Available from: <https://pubmed.ncbi.nlm.nih.gov/33782057/>.
- X. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2020;382:1883–93.
- XI. Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and

The Therapeutic Efficacy and Clinical Implications of Vericiguat in the Management of Heart Failure with Reduced Ejection Fraction (HFrEF)

- preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved EF (SOCRATES-preserved) study. *Eur Heart J* 2017;38:1119–27.
- XII. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CSP, Maggioni AP, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-reduced randomized trial. *JAMA* 2015;314:2251–62.
- XIII. Ponikowski P, Almayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. *Eur J Heart Fail* [Internet] 2021;23:1300–12. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/ehf.2285>
- XIV. Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. *JACC Heart Fail* [Internet] 2020;8:931–9. Available from: <https://www.sciencedirect.com/science/article/pii/S2213177920304996>.
- XV. Lam CSP, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. *JAMA Cardiol* 2021;6:706–12.